Biomotion Sciences Net Income Over Time
| SLXNW Stock | 0.03 0.00 0.000003% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biomotion Sciences Performance and Biomotion Sciences Correlation. Biomotion | Build AI portfolio with Biomotion Stock |
What growth prospects exist in Stock sector? Can Biomotion capture new markets? Factors like these will boost the valuation of Biomotion Sciences. If investors know Biomotion will grow in the future, the company's valuation will be higher. Valuation analysis balances hard financial data with qualitative growth assessments. While each Biomotion Sciences valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Understanding Biomotion Sciences requires distinguishing between market price and book value, where the latter reflects Biomotion's accounting equity. The concept of intrinsic value - what Biomotion Sciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Market sentiment, economic cycles, and investor behavior can push Biomotion Sciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Biomotion Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomotion Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Biomotion Sciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Biomotion Sciences and related stocks such as Virpax Pharmaceuticals, Vincerx Pharma Common, and Dermata Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VINC | (54 K) | (54 K) | (54 K) | (54 K) | (54 K) | (54 K) | (54 K) | (54 K) | (54 K) | (54 K) | (10.7 M) | (39.3 M) | (65.4 M) | (40.2 M) | (30.1 M) | (27.1 M) | (28.4 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (7.9 M) | (9.6 M) | (7.8 M) | (12.3 M) | (11.1 M) | (11.6 M) |
| PIII | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (42 M) | (31.4 M) | (270.1 M) | (270.1 M) | (57.8 M) | (135.8 M) | (122.3 M) | (128.4 M) |
| FOXO | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (38.5 M) | (95.3 M) | (26.5 M) | (12.4 M) | (14.3 M) | (15 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (15 M) | (13.5 M) | (12.9 M) |
| ACON | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4.6 M) | (5 M) | (7.1 M) | (4.9 M) | (7 M) | (6.3 M) | (6.6 M) |
| PPBT | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | (5.3 M) | (4.2 M) | (12.1 M) | (12.2 M) | (5.2 M) | (5.8 M) | (28 M) | (18.4 M) | (21.7 M) | (19.9 K) | (7.2 M) | (6.5 M) | (6.8 M) |
| AKTX | (675 K) | (2.1 M) | (1.4 M) | (3.6 M) | (9.6 M) | (45.3 M) | (18.1 M) | (27.9 M) | (19.9 M) | (16.8 M) | (17.1 M) | (17.4 M) | (17.7 M) | (10 M) | (19.8 M) | (17.8 M) | (18.7 M) |
Biomotion Sciences and related stocks such as Virpax Pharmaceuticals, Vincerx Pharma Common, and Dermata Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Biomotion Sciences financial statement analysis. It represents the amount of money remaining after all of Biomotion Sciences Warrant operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Biomotion Sciences Warrant | SLXNW |
| Business Address | The Goldyne Savad |
| Exchange | NASDAQ Exchange |
null 0.0326
Additional Tools for Biomotion Stock Analysis
When running Biomotion Sciences' price analysis, check to measure Biomotion Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomotion Sciences is operating at the current time. Most of Biomotion Sciences' value examination focuses on studying past and present price action to predict the probability of Biomotion Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomotion Sciences' price. Additionally, you may evaluate how the addition of Biomotion Sciences to your portfolios can decrease your overall portfolio volatility.